相关实验视频
Updated: Jun 29, 2025
10:36
Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
19.4K
肥胖妇女怀孕期间多菌株益生菌影响婴儿肠道微生物组发育:来自随机,双盲,安慰剂对照研究的结果
Sofie Ingdam Halkjær1, Malene Refslund Danielsen1, Victoria E de Knegt2
1Gastrounit,Medical Division, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
Gut microbes
|April 9, 2024
概括
怀孕期间母亲使用益生菌并没有直接改变婴儿肠道微生物组 (GM) 的组成. 然而,它可能间接减少婴儿中与肥胖相关的细菌,这表明对婴儿代谢健康的潜在益处.
科学领域:
- 微生物学 微生物学
- 围产期健康 围产期健康
- 肠道微生物组研究研究
背景情况:
- 众所周知,益生菌调节肠道微生物群 (GM) 并可能影响肥胖风险.
- 孕妇在怀孕期间服用益生菌补充剂对婴儿转基因和健康结果的影响需要进一步调查.
研究的目的:
- 评估一项随机对照试验的可行性,调查Vivomixx® (多菌株益生菌) 对婴儿肠道微生物群和围产期健康的影响.
- 为了确定母亲的产前益生菌给药是否会改变婴儿的转基因成分和健康结果,直到9个月的产后.
主要方法:
- 一项随机,双盲,安慰剂控制的可行性研究,涉及50名肥胖的孕妇.
- 婴儿在产后9个月内被监控进行人体测量,便样本分析 (GM组成) 和健康/饮食问卷.
- 分析的重点是转基因多样性,差异丰度和特定品种的存在.
主要成果:
- 该研究表明了可行性,参与者对后续访问和样本采集的意愿很高.
- 母亲的益生菌补充剂没有改变婴儿的转基因多样性或丰度,也没有垂直转移益生菌菌株.
- 在益生菌组的婴儿中观察到与肥胖相关的Collinsella的减少,在安慰剂组的Akkermansia的减少,这表明间接的母性转基因影响.
- 婴儿转基因在3天后受到分娩方式和母亲使用抗生素的显著影响.
结论:
- 母亲产前益生菌补充剂对婴儿肠道微生物组合产生潜在的间接影响,特别是减少与肥胖相关的一般性疾病.
- 产生的方式和母亲的抗生素暴露是婴儿肠道微生物组发育的关键早期决定因素.
- 需要进一步的研究来证实这些发现,并探索对婴儿健康和肥胖预防的长期影响.
更多相关视频
11:44A Primary Human Trophoblast Model to Study the Effect of Inflammation Associated with Maternal Obesity on Regulation of Autophagy in the Placenta
Published on: September 27, 2017
11.4K
11:22Microbiota Analysis Using Two-step PCR and Next-generation 16S rRNA Gene Sequencing
Published on: October 15, 2019
27.9K
相关概念视频
01:23Anatomy of the Intestines
71.8K
Although digestion of proteins, carbohydrates, and lipids may begin in the stomach, it is completed in the intestine. The absorption of nutrients, water, and electrolytes from food and drink also occurs in the intestine. The intestines can be divided into two structurally distinct organs—the small and large intestines.
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the...
71.8K
01:07Teratogenicity
2.4K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K